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Extracts of Tripterygium wilfordii Hook F have been used to
treat glomerulonephritis for more than 30 years in China with
dramatic antiproteinuric effects. Triptolide, a diterpene
triepoxide, is one of the major active components of these
extracts. To clarify its antiproteinuric effects we induced
podocyte injury by puromycin aminonucleoside. Triptolide
effectively reduced the proteinuria induced by puromycin in
nephrotic rats without reducing the glomerular filtration rate.
The antiproteinuric effect was associated with improvement
in the foot process effacement, a decrease in the podocyte
injury marker desmin as well as the restoration of nephrin
and podocin expression and distribution. In cultured
mouse podocytes triptolide pretreatment prevented the
puromycin-induced disruption of the actin cytoskeleton
and microfilament-associated synaptopodin while protecting
nephrin and podocin expression. Triptolide suppressed
reactive oxygen species generation and p38 mitogen-
activated protein kinase activation while restoring RhoA
signaling activity. These results show that triptolide
ameliorates puromycin aminonucleoside-mediated podocyte
injury in vivo and in vitro.
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Proteinuria is the main clinical manifestation of podo-
cyte diseases including minimal change disease, focal
segmental glomerular sclerosis, and membranous nephro-
pathy.1–3 It is believed that podocyte injury is a major
contributor to severe proteinuria. There are expanding
literatures elucidating the molecular events of podocyte
injury, although, the treatment for podocyte diseases are
far from satisfactory. Therefore, more effective drugs are
desirable to improve the treatment for patients with podocyte
diseases.
Extracts of Tripterygium wilfordii Hook F (TWHF) have
been used in the treatment of glomerulonephritis for more
than 30 years in China. Tablets made from the extracts of
TWHF showed very dramatic effects on decreasing protein-
uria in patients with minimal change disease, focal segmental
glomerular sclerosis and membranous nephropathy.4 Addi-
tionally, extracts of TWHF could alleviate glomerular
albumin permeability induced by protamine, tumor necrosis
factor (TNF-a) and the serum from patients with focal
segmental glomerular sclerosis in vitro.5 It is an intriguing
possibility that further characterization of the effective
component of TWHF on podocyte lesion will provide a
new mechanism based medicine for the treatment of
podocyte diseases. Triptolide, a diterpene triepoxide, was
identified as one of the major active components of TWHF.
Recent reports showed that triptolide has strong immuno-
suppressive and anti-inflammatory activities.6–10 In previous
work, we found that triptolide could effectively reduce
proteinuria, alleviate glomerular immune injuries, and
remarkably improve podocyte lesion in rat model with
passive Heymann nephritis.11 All these findings implicated
that beneficial therapeutic effects of triptolide on proteinuria
might be mediated, at least in part, by a protective effect on
podocytes.
Injection of puromycin aminonucleoside (PAN) to rats
produces severe proteinuria and mimics the lesions of
minimal change or focal segmental glomerular sclerosis.12 It
was found that PAN specifically injured podocytes, leading to
foot process effacement, actin cytoskeleton disorganization,
decreased expression and abnormal distribution of slit
diaphragm proteins, including nephrin and podocin,13–15
resulting in a well-described model of podocyte injury. To
address the question of whether triptolide has a direct action
on podocytes, an animal model of PAN was used to evaluate
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the effect of triptolide in vivo. In addition, an in vitro
study was performed using immortalized podocytes to
confirm the direct protective effects of triptolide on podocyte
injuries and to explore the underlying mechanism of
triptolide action.
RESULTS
Triptolide reduced proteinuria in PAN nephrosis rats
Proteinuria emerged at 5 days after single PAN injection,
reached the peak at 10 days, was persistent at 14 days, and
decreased at 21 days. The antiproteinuria effect of triptolide
was evaluated by its preventing and treatment effect,
respectively. It was found that proteinuria was significantly
reduced at 5 days in the triptolide prevention group
compared with PAN rats (Po0.01). The reducing effect of
triptolide on proteinuria was persistent obviously at 10 days
(Po0.01), 14 days (Po0.01), and maintained at 21 days
(Po0.01). At 21 days, proteinuria was restored to normal
(P40.05, prevention group versus normal control). The
similar effect on proteinuria was observed in the triptolide
treatment group. There was no significant difference bet-
ween the triptolide prevention group and treatment group
(Table 1).
Triptolide improved the abnormalities of serum albumin,
cholesterol and triglyceride in PAN nephrosis rats
The restoration of serum albumin level after treatment
paralleled to that of decrease of proteinuria. The serum
albumin level was markedly elevated at 5 days in triptolide
prevention group compared with PAN rats (Po0.05). The
significant effect was observed at 10 days (Po0.01). In the
triptolide prevention group, serum albumin level was
restored to normal at 21 days. Meanwhile, restoration of
serum albumin in the triptolide treatment group was similar
to that in the prevention group, and there was no significant
difference between the two groups (Table 2).
In addition, the level of triglyceride in both the triptolide
prevention and treatment groups was significantly decreased
compared with those in PAN rats at 10 and 14 days
(Po0.01), and returned to normal range at 21 days (Table 3).
The levels of cholesterol decreased at 14 days and was back to
normal at 21 days both in the triptolide prevention and
treatment groups (Table 4).
No statistically significant difference in serum creatinine
levels was found among the three groups at the time when
rats were killed (data not shown). The levels of aspartate
aminotransferase and alanine aminotransferase remained
normal in triptolide-treated rats (data not shown).
Table 1 | The effect of triptolide on proteinuria in PAN nephrosis rats (mg/24 h)
5 days 10 days 14 days 21 days
Normal control 3.59±1.90 4.06±1.17 3.99±1.46 3.64±2.02
PAN model 29.22±4.46** 88.74±14.16** 40.19±8.18** 12.71±4.77**
Prevention 12.03±3.72**mm 20.24±4.06**mm 12.32±2.73**mm 5.35±1.70mm
Treatment 14.97±4.54**mm 22.91±5.90**mm 14.38±3.81**mm 4.13±2.43mm
PAN, puromycin aminonucleoside.
*Po0.05 versus normal control; **Po0.01 versus normal control; mmPo0.01 versus the PAN model (n=5 animals per group).
Table 2 | The effect of triptolide on serum albumin level in PAN nephrosis rats (g/l)
5 days 10 days 14 days 21 days
Normal control 34.32±1.26 34.16±1.62 33.73±1.94 35.46±0.76
PAN model 24.14±3.93** 17.3±3.23** 23.55±4.34** 30.96±2.17**
Prevention 28.36±4.18**m 25.23±3.07**mm 28.35±1.99**m 35.33±0.88m
Treatment 27.32±4.30**m 23.06±3.79**mm 27.74±3.28**m 34.52±2.10m
PAN, puromycin aminonucleoside.
*Po0.05 versus normal control; **Po0.01 versus normal control; mPo0.05 versus the PAN model; mmPo0.01 versus the PAN model (n=5 animals per group).
Table 3 | The effect of triptolide on triglyceride level in PAN
nephrosis rats (mmol/l)
5 days 10 days 14 days 21 days
Normal control 1.66±0.22 1.55±0.15 1.69±0.19 1.62±0.23
PAN model 3.21±1.11** 7.31±2.96** 4.81±1.05** 2.00±0.78
Prevention 2.14±0.44* 4.61±1.54**mm 1.87±0.36mm 1.65±0.14
Treatment 2.11±0.46* 4.91±1.63**mm 2.01±0.74mm 1.64±0.40
PAN, puromycin aminonucleoside.
*Po0.05 versus normal control; **Po0.01 versus normal control; mmPo0.01 versus
the PAN model (n=5 animals per group).
Table 4 | The effect of triptolide on cholesterol level in PAN
nephrosis rats (mmol/l)
5 days 10 days 14 days 21 days
Normal control 2.37±0.34 2.23±0.43 2.28±0.29 2.30±0.29
PAN model 3.54±1.03* 4.83±1.33** 3.79±1.28* 2.44±0.44
Prevention 2.74±0.92 3.77±1.16* 3.09±0.99 2.34±0.35
Treatment 2.77±0.91 3.89±1.27* 3.02±1.09 2.30±0.42
PAN, puromycin aminonucleoside.
*Po0.05 versus normal control; **Po0.01 versus normal control (n=5 animals
per group).
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The influence of triptolide on GFR
To exclude the possibility that triptolide reduced proteinuria
by decreasing glomerular filtration rate (GFR), we measured
GFR in normal control, PAN model, triptolide prevention,
and treatment groups (five rats in each group) at 5, 10,
and 14 days, respectively. We found no significant changes of
GFR in the PAN model, triptolide prevention, and treatment
groups at 5 and 14 days of PAN injection, compared with
normal control. And at 10 days, GFR was significantly lower
in the PAN model than in normal control (Po0.05); how-
ever, no significant differences were found between PAN
model and the triptolide prevention and treatment groups
(P40.05). GFR of both triptolide prevention and treatment
groups did not differ from that of normal level (P40.05;
Figure 1). Therefore, the results confirmed that triptolide
reduced proteinuria by the protective and reversing effect on
podocyte injuries in PAN nephrosis rats, rather than by
decrease of GFR.
Triptolide ameliorated podocyte foot process effacement
in PAN nephrosis rats
Light-microscopy examination showed no histological
changes of global or focal segmental glomerulosclerosis,
interstitial fibrosis, or tubular atrophy in all the three groups
(Figure 2).
Foot process effacement could be seen at 5 days after
PAN injection in PAN rats (Po0.01 versus normal control).
The most extensive foot process effacement that developed
at 10 days paralleled with massive proteinuria. The effaced
foot processes were just like sheet covering the glomerular
basement membrane, and the slit diaphragm gap disap-
peared. The change persisted at 14 days and got recovery at
21 days (Figure 3a–m).
As showed in Table 5, at each time point (5, 10, 14, and 21
days), foot process widths were significantly decreased in the
triptolide prevention group compared with that in PAN
model rats (Po0.01), but were still wider than normal
controls (Po0.01). The foot process size was restored to
normal at 21 days in triptolide prevention group. The similar
improvement of foot process effacement was observed in
triptolide treatment group (Table 5; Figure 3a–m).
Triptolide restored the expression and distribution of
nephrin and podocin in PAN nephrosis rats
By fluorescence microscopy, the expression intensity and
distribution pattern of nephrin and podocin in glomeruli
were observed. The staining of nephrin and podocin was
revealed as a linear pattern along glomerular capillary wall in
the normal control rats. At 5 days, the expression of nephrin
and podocin was significantly reduced and the distribution
became dot-like. At 10 days, the peak point of proteinuria,
the changes of expression intensity and distribution both of
nephrin and podocin were distinctly obvious. The linear
staining pattern disappeared with remarkably decreased
expression intensity of nephrin and podocin. At 14 days,
the expression intensity was increased, but distribution still
remained dot-like both in nephrin and podocin. At 21 days,
the distribution of nephrin and podocin got better. Triptolide
could significantly improve the expression of nephrin and
podocin, and reverse the redistribution of nephrin and
podocin. Compared with PAN model rats, the expressions
of nephrin and podocin were significantly increased in both
of the triptolide prevention and treatment groups at 10 days,
and distribution appeared linear at 14 days. The expression
and distribution of nephrin and podocin were significantly
recovered at 14 days and completely restored to normal at
21 days (Figure 4a–m, n–z).
Triptolide decreased the expression of desmin in PAN
nephrosis rats
In normal control rats, trace amount of desmin was found in
glomeruli. In PAN model rats, the expression of desmin
increased significantly at 5 days, and reached its peak at
10 days. At 14 days, desmin expression began to decrease, and
at 21days further decreased but remained still higher than
that in normal controls. Compared with PAN rats, expression
of desmin was significantly decreased in both the triptolide
prevention and treatment groups at 5, 10, 14, and 21 days.
At 21 days, expression of desmin returned to normal levels
(Figure 5a–m).
Triptolide protected podocytes against PAN induced
cytoskeleton disruption
F-actin filaments in cultured podocytes were distributed as
stress fiber-like bundles along the axis or into the process of
cells. PAN caused podocytes cytoskeleton reorganization in a
dose-dependent manner. Treatment of podocytes with 25 and
50mg/ml PAN for 24 h only caused F-actin disorderliness and
rarefaction of filaments. Treatment with 100mg/ml PAN resul-
ted in cell retraction and dramatic loss of actin stress-fiber
organization (Figure 6a–d), and hence, cytoskeletal changes were
accompanied by loss of synaptopodin staining (Figure 6q–s).
However, when cells were preincubated with triptolide for
30 min before exposure to PAN, podocytes avoided the above
changes. The protective effect of triptolide on cytoskeleton was
also dose dependent (Figure 6i–l). At the dose of 3 ng/ml,
triptolide almost completely restored normal cytoskeleton in
podocytes without affecting cell survival (Figure 6m–p).
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Figure 1 | GFR measurement in normal control, PAN nephrosis
and triptolide-treated rats. *Po0.05 versus normal control. BW,
body weight.
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To ensure that cytoskeleton disruption effect of PAN were
not due to the apoptosis of podocytes, we performed Hoechst
staining. Our results showed no significant difference
in apoptosis between PAN-treated (o0.2% of total cells),
triptolide pretreatment (o0.3% of total cells), and untreated
(0%) podocytes (n4300 cells for each treatment) (Figure
6e–h and m–p). For subsequent experiments, triptolide was
used at concentration of 3 ng/ml and PAN 100 mg/ml.
To assess whether triptolide could recover podocytes from
prior injury, podocytes were pretreated with 100 mg/ml PAN
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Figure 2 | Renal histology changes of PAN nephrosis and triptolide-treated rats. (a) Normal control. (b–k) PAN model groups of
5, 10, 14, and 21 days. (c–l) Triptolide prevention groups of 5, 10, 14, and 21 days. (d–m) Triptolide treatment groups of 5, 10, 14, and
21 days. Original magnification  400.
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for 24 h. Then cells were transferred to triptolide medium
(3 ng/ml) for an additional 24 or 72 h. Podocytes incubated
with triptolide for only 24 h following PAN treatment
had sparse stress fibers, and staining of F-actin in them
was stronger than in those without triptolide incubation.
After 72 h of incubation with triptolide medium, podo-
cytes reformed robust network of actin stress fibers
(Figure 7). Synchronously, disrupted distribution of synap-
topodin by PAN was restored after treatment with triptolide
(Figure 8).
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Figure 3 | The effect of triptolide on foot process in PAN nephrosis rats. (a) Normal control. (b–k) PAN model groups of 5, 10, 14, and
21 days. (c–l) Triptolide prevention groups of 5, 10, 14, and 21 days. (d–m) Triptolide treatment groups of 5, 10, 14, and 21 days.
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Triptolide protected podocytes against PAN-induced
nephrin and podocin alteration
The effects of triptolide on the expression and distribution of
nephrin and podocin were further confirmed in cultured
podocytes. PAN treatment (100mg/ml, 24 h) decreased the
expression of nephrin and podocin in cultured podocytes.
However, triptolide pretreatment could protect podocytes
against PAN-induced injuries (Figure 9a–c, d–f). These observa-
tions were consistent with the results of nephrin and podocin
expression analyzed by flow cytometry (Figure 10a and b).
Additionally, triptolide could recover PAN-induced
injuries on nephrin and podocin expression in podocytes
(Figure 11a–f). Podocytes were treated with PAN (100 mg/ml)
for 24 h followed by triptolide medium (3 ng/ml) for further
72 h; the expressions of nephrin and podocin were signifi-
cantly improved after triptolide treatment. This result was
also confirmed by flow cytometry (Figure 12a and b).
Triptolide inhibited PAN-induced cellular ROS generation
To unravel the mechanisms underlying the protective effect of
triptolide on podocytes, PAN-induced intracellular produc-
tion of reactive oxygen species (ROS) was examined. PAN
(100mg/ml) significantly increased ROS generation in podo-
cytes. This effect was observed at 30 min and maintained
for 6 h (Figure 13a). ROS level at 30 min was twofold higher
than that of basal level after PAN treatment. Pretreatment of
podocytes with triptolide (3 ng/ml) or antioxidant N-acetyl-
cysteine (NAC, 10 mmol/l) before PAN exposure led to a
significant reduction in the cellular ROS level (Figure 13b).
Triptolide inhibited PAN-induced p38 MAPK activation
To characterize the intracellular signaling pathway associated
with the protective effects of triptolide in podocytes,
phosphorylation of p38 mitogen-activated protein kinase
(MAPK) was analyzed. Treatment of podocytes with PAN
induced a strong increase in phosphorylation of p38 MAPK.
It increased at 3 h and was maintained for 12 h after PAN
treatment (Figure 13c). Pretreatment of triptolide (3 ng/ml)
effectively suppressed PAN-induced phosphorylation of p38
MAPK (Figure 13d). Triptolide did not affect basal
phosphorylation of p38 MAPK.
Cellular ROS and activations of p38 MAPK are required for
PAN-induced actin reorganization in podocytes
We next examined the role of ROS and p38 MAPK phos-
phorylation in modulating PAN-induced actin reorganization
described in Figure 6. Western blots showed that NAC
(10 mmol/l) significantly suppressed PAN-induced phosphory-
lation of p38 MAPK. Both NAC (10 mmol/l) and p38 inhibitor
SB-203580 (25mmol/l) effectively inhibited PAN-induced
cytoskeleton disarrangement (Figure 13e–h).
Triptolide restored the activity of RhoA in podocytes
RhoA has been suggested to play an important role in
cytoskeleton reorganization. To investigate whether RhoA-
signaling pathways are involved in the effect of triptolide on
podocytes, we performed RhoA activation assay. As shown in
Figure 14a, PAN treatment induced strong decline in RhoA
activity at 30 min and the low level of activity was maintained
till 12 h. When cells were pretreated with triptolide prior to
PAN exposure, RhoA activity was not decreased and normal
level was maintained. Total protein level of RhoA was not
affected by PAN and triptolide treatment during the time
of the test. However, the increase of RhoA activation
was markedly inhibited by the specific RhoA inhibitor, C3
exoenzyme (1mg/ml). Immunofluorescence staining was
consistent with the result from western blotting, showing
that inhibition of RhoA activity by C3 exoenzyme abolished
the protective effect of triptolide on PAN-induced F-actin
dissociation (Figure 14b–c). These results strongly suggested
that restoration of RhoA activity mediated the protective
effect of triptolide.
We further examined whether p38 MAPK pathway cross-
talked with RhoA-signaling pathways in regulating PAN-
induced cytoskeleton disruption. Western blot results showed
that C3 exoenzyme (1 mg/ml) did not alter p38 MAPK
phosphorylation in response to PAN, and neither NAC
(10 mmol/l) nor SB-203580(25 mmol/l) altered RhoA activity
(Figure 15). Our data suggested that p38 MAPK and RhoA
are two independent signaling pathways involved in regula-
tion of PAN-induced cytoskeleton disorganization.
DISCUSSION
The concept that podocyte has the major role in the develop-
ment of proteinuria and progression of glomerulosclerosis,
leads us to find new approaches to target podocyte lesions.
These efforts have generated numerous findings showing that
certain reagents, such as retinoids, fluvastatin and darbe-
poetin, decreased proteinuria by ameliorating podocyte
injury.16–18 Here, we reported another reagent, triptolide,
showing potent efficacy in reducing proteinuria and restoring
podocyte injury in PAN-induced nephrosis.
Table 5 | The effect of triptolide on foot process width in PAN nephrosis rats (nm)
5 days 10 days 14 days 21 days
Normal control 271±64 268±60 267±57 277±66
PAN model 1808±316** 4929±1002** 2231±664** 876±264**
Prevention 863±209**mm 1307±279**mm 881±211**mm 270±54mm
Treatment 880±218**mm 1444±291**mm 906±245**mm 274±61mm
PAN, puromycin aminonucleoside.
**Po0.01 versus normal control; mmPo0.01 versus the PAN model (n=5 animals per group).
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Results of this study demonstrated that triptolide
effectively reduced proteinuria and ameliorated podocyte
foot process effacement in PAN nephrosis rats. Recovery
from podocyte injury was further proved by reduction of
desmin expression in PAN rats after treatment with
triptolide. In addition, the alterations of slit diaphragm
proteins, nephrin and podocin, induced by PAN were
remarkably restored by triptolide. In vitro studies further
confirmed that triptolide protected and reversed PAN-
induced cytoskeleton disruption, as well as distribution of
nephrin and podocin expression, in podocytes. It was found
that the above action of triptolide may be mediated through
ROS–p38 MAPK and RhoA pathway.
PAN-induced nephrosis is characterized by heavy protein-
uria and podocyte foot process effacement. Studies have
correlated podocyte slit diaphragm proteins and cytoskeletal
abnormalities with the onset of proteinuria in PAN-induced
nephrosis.13,19 Recently, it has been revealed that the slit
diaphragm proteins complex (nephrin–podocin–CD2AP) is
an important component in maintaining glomerular filtra-
tion barrier. In PAN-induced nephrosis models, the expres-
sion and distribution of nephrin and podocin were found
abnormal before the onset of proteinuria.20,21 In addition to
the morphological changes of foot processes and expressional
alterations of slit diaphragm proteins, upregulation of
various proteins, such as desmin, B7-1, and heat-shock
protein 27, has been noted in podocytes.22–24 Among them,
desmin staining has been used frequently as a marker of
podocyte injury because of its notable changes.
In this study, we applied a minimal change disease model
induced by PAN for our observations, which was demon-
strated by light microscopy and electron microscopy. After
PAN injection, proteinuria peaked at 10 days in nephrotic
rats. Simutaneously, podocyte foot process effacement was
the most obvious and decreased expression and redistribu-
tion of nephrin and podocin were also remarkable at this
point. Coincidently, the podocyte injury marker, desmin, was
increased conspicuously. The results provided evidence that
massive proteinuria had correlations with podocyte injuries.
In comparison, at 10 days after triptolide treatment of
PAN nephrosis rats, we found that proteinuria reduced
significantly, accompanied by improvement of podocyte foot
process effacement and restoration of both nephrin and
podocin expression as well as desmin expression. All these
findings indicated that the antiproteinuric effect of triptolide
was strongly associated with recovery of podocyte injury.
Oxidative stress initiation and subsequent apoptosis have
been thought to be associated with podocyte impairment
induced by PAN.25,26 In our study, we have not found any
apoptotic cells in the kidney tissues of nephrotic rats at any
time points at the dose of 8 mg/100 g body weight, or not in
triptolide prevention and treatment rats (data not shown). It
was reported that calcineurin inhibitors reduced proteinuria
at the cost of significantly decreased GFR.27,28 By compa-
rison, we observed that triptolide had no effect on GFR
levels at the administered dose, which further proved its
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Figure 4 | The effect of triptolide on nephrin and podocin
expression and distribution in PAN nephrosis rats. (a–m) Nephrin
and (n–z) podocin. (a, n) Normal control. (b–k) and (o–x) PAN model
groups of 5, 10, 14, and 21 days. (c–l, p–y) Triptolide prevention
groups of 5, 10, 14, and 21 days. (d–m, q–z) Triptolide treatment
groups of 5, 10, 14, and 21 days. Original magnification  400.
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independent action of reducing proteinuria. Combined with
histological evidence, the result also suggested that triptolide
had no nephrotoxicity at the dosage used.
To verify that triptolide has directly protective effect on
podocyte injuries, and to explore the underlying mechanism
of triptolide action, we further performed in vitro studies.
Actin cytoskeleton plays a central role in regulating podocyte
structure and acts as the critical cytoskeletal protein
anchoring focal adhesion and slit diaphragm proteins for
maintaining the barrier function. These cytoskeletal proteins
are responsible for attachment between adjacent podo-
cytes.29–31 Any alterations in actin might lead to changes
in the structure and function of podocytes.19 In this study,
it was found that the structure of actin cytoskeleton
and synaptopodin was disrupted by PAN. Pretreatment with
triptolide could prevent disruption of actin filaments and
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Figure 5 | The effect of triptolide on the expression of desmin in PAN nephrosis rats. (a) Normal control. (b–k) PAN model groups of
5, 10, 14, and 21 days. (c–l) Triptolide prevention groups of 5, 10, 14, and 21 days. (d–m) Triptolide treatment groups of 5, 10, 14, and
21 days. Original magnification  400.
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synaptopodin induced by PAN. Furthermore, we observed
the restoration effect of triptolide on cytoskeleton disrup-
tion induced by PAN. Triptolide enhanced recovery of
PAN-induced actin filaments and synaptopodin disruption.
In addition, the decreased expression of nephrin and podocin
induced by PAN could be protected by triptolide. This effect
not only was observed in triptolide pretreated cells, but also
could be seen even podocyte injury occurred. The finding
that triptolide protected and reversed podocyte injury added
more clinical application of using triptolide for patients with
podocyte diseases.
We further asked what is the underlying mechanism by
which triptolide exerted the protective effect on podocytes.
Overproduction of ROS has been proved to mediate
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Figure 6 | Triptolide pretreatment protected podocytes against PAN-induced cytoskeleton disruption. (a–h) PAN caused podocytes
cytoskeleton reorganization in a dose-dependent manner without causing cell apoptosis. Normal control (a, e), 25mg/ml PAN (b, f),
50mg/ml PAN (c, g), and 100 mg/ml PAN (d, h). (i–p) Triptolide pretreatment protected podocytes actin cytoskeleton from PAN-induced
injury in a dose-dependent manner. 100 mg/ml PAN treated podocytes (i, m), 0.5 ng/ml triptolide preincubation (j, n), 1 ng/ml triptolide
preincubation (k, o), 3 ng/ml triptolide preincubation (l, p). Red fluorochrome corresponds to F-actin and blue to the nucleus. Original
magnification  400. (q–s) Triptolide pretreatment protected podocytes synaptopodin from PAN-induced injury. Untreated podocytes
(q), PAN (100 mg/ml, 24 h) treated podocytes (r), podocytes were preincubated for 30 min with triptolide before PAN exposure (s). Green
fluorochrome corresponds to synaptopodin and red to the nucleus. Original magnification  400.
604 Kidney International (2008) 74, 596–612
o r i g i n a l a r t i c l e C-X Zheng et al.: Triptolide protects PAN-induced podocyte injury
succedent podocyte injury induced by PAN toxicity.32–34
Besides podocytes, triptolide has previously been shown to
inhibit ROS generation in PC12 neuronal cell, which shares
many cell biological characteristics with podocytes.35–37 We
observed that ROS generation induced by PAN in podocytes
was significantly inhibited by triptolide treatment. Further-
more, our study found that triptolide inhibited p38 MAPK
activation induced by PAN. p38 was the major MAP kinase
activated by oxidative stress in several cells under various
stimuli.38–40 It was believed that activation of p38 MAPK was
related to podocyte injury and development of proteinuria, as
well as actin cytoskeleton disruption. Pretreatment of PAN
nephrosis rats with p38 MAPK inhibitor completely inhibited
p38 MAPK activation and proteinuria.41 A study by Susztak
et al.39 also has shown that glucose-induced ROS caused
podocyte apoptosis and depletion via p38 MAPK pathway. In
our study, we showed that both antioxidant NAC and p38
MAPK inhibitor SB-203580 successfully reduced PAN-
induced podocyte damage. In addition, NAC could effectively
suppress PAN-induced phosphorylation of p38 MAPK. These
results indicated that ROS generation and subsequent p38
MAPK phosphorylation mediated PAN-induced podocyte
injury. Therefore, our observations demonstrated that
triptolide prevented podocyte from damage by inhibiting
ROS generation and p38 MAPK phosphorylation.
Small GTPase-Rho-mediated signal transduction is a
ubiquitous pathway in various kinds of cells. It is a direct
upstream signaling that controls actin filament reorganiza-
tion, directing cellular behaviors and phenotypic alterations.
RhoA also plays an import role in podocyte cytoskeleton
organization.19 Proper regulation of Rho GTPase is required
for maintaining differentiation of podocytes.42 We hypothe-
sized that RhoA might also contribute to the protective
effects of triptolide against PAN-induced lesions. We found
that triptolide pretreatment restored RhoA activity, which
was suppressed in PAN-treated podocytes. In addition, C3
exoenzyme, a highly selective inhibitor of RhoA, abolished
the effect of triptolide, as shown by western blotting
and immunofluorescence staining. These findings strongly
suggested that restoration of RhoA activity mediated the
protective effect of triptolide.
Although these results suggested that the protective effect
of triptolide on PAN-induced podocyte injury targeted at the
RhoA- and p38 MAPK-signaling pathways, it needed further
elucidation of the relationship between RhoA- and p38
MAPK-signaling pathways. Moreover, several studies have
suggested that the two pathways of RhoA and p38 MAPK
could crosstalk and/or cooperate with each other.43,44
Therefore, we performed a set of experiments to examine
these possibilities. First, we found that C3 exoenzyme did not
affect phosphorylation of p38 MAPK. And then, we observed
that NAC and p38 MAPK inhibitor, SB-203580, did not
affect PAN-induced RhoA activity. Taken together, these
data supported the fact that p38 MAPK and RhoA are
two independent signaling pathways in regulation of
PAN-induced cytoskeleton disorganization.
In conclusion, triptolide showed a prominent antiprotein-
uric effect on PAN-induced nephrosis. This effect was
characterized by improvement of foot process effacement,
recovery of podocyte injury marker, desmin, and restoration
of nephrin and podocin redistribution. In vitro study further
proved that triptolide could protect podocyte from PAN-
induced cytoskeleton disruption, abnormality of nephrin
and podocin expression. The above action of triptolide might
contribute to inhibition of ROS generation and subsequent
p38 MAPK pathway, as well as restoration of RhoA activity.
MATERIALS AND METHODS
Reagents
Triptolide (C20H24O6, molecular weight 360) was obtained from
Chinese National Institute for Control of Pharmaceutical and
Biological Products (Beijing, China). The purity of triptolide was
detected by high-performance liquid chromatography to be 99.99%.
Triptolide was reconstituted in 0.01% dimethyl sulfoxide and freshly
diluted with culture medium before use. Dimethyl sulfoxide’s
a b
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Figure 7 | Triptolide reversed PAN-induced podocytes actin
cytoskeleton disruption. Untreated podocytes (a). PAN
(100mg/ml, 24 h)-treated podocytes (b). Podocytes were treated
with PAN (100mg/ml, 24 h) followed by the culture medium with
triptolide for further 24 and 72 h (c, e). Podocytes were treated
with PAN (100 mg/ml, 24 h) followed by culture medium without
triptolide for further 24 and 72 h (d, f). Red fluorochrome
corresponds to F-actin. Original magnification  400.
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concentration in in vitro studies was less than 0.002% (v/v). PAN
was purchased from Sigma (St Louis, MO, USA).
Animal experimental design
Male Sprague–Dawley rats (Laboratory Animals Center of Nanjing
University School of Medicine, Nanjing, China) weighing 150–180 g
were fed standard diet. All experiments conducted on rats were in
accordance with the guidelines for the care and use of laboratory
animals approved by Nanjing University School of Medicine. PAN
nephrosis was induced by a single intravenous injection of PAN
(8 mg/100 g body weight). Rats were divided into normal control,
PAN model, triptolide prevention group, and triptolide treatment
group. For the prevention group, triptolide treatment (200 mg/kg per
day orally) was started 2 days before PAN injection and continued
throughout the experiment. While for the treatment group,
triptolide was started 1 day after PAN injection. On each time
point of 5, 10, 14, and 21 days, 24 h urine collection was performed
using a metabolic cage and blood samples were collected for
biochemical analysis. Simultaneously, rats were killed under
ketamine anesthesia. Renal tissues were processed for light
microscopy, immunofluorescence staining, and electron microscopy.
Urinary protein concentration was measured with Coomassie
brilliant blue G-250. Serum albumin, cholesterol, triglyceride,
alanine aminotransferase, aspartate aminotransferase, and serum
creatinine levels were measured by HITACHI7080 (Tokyo, Japan).
Light microscopy
Kidney tissues were fixed in 10% formalin, dehydrated in graded
alcohol, and embedded in paraffin. Sections measuring 2 mm were
cut and stained with hematoxylin and eosin, periodic acid–Schiff
regent, periodic acid–sliver methenamine, and Masson’s trichrome.
All slides were evaluated by the same pathologist who was unaware
of the nature of the experimental groups, using a Nikon E800
microscope.
Transmission electron microscopy
Blocks of renal cortical tissue (l mm3) were fixed in cold 3.75%
glutaraldehyde for 4 h and postfixed in phosphate-buffered 1%
osmium tetroxide for 2 h. And then specimens were embedded in
Epon 812 ultrathin sections (70 nm). The specimens were examined
and photographed with Hitachi 7500 transmission electron micro-
scopy (Tokyo, Japan).
GFR measurement
GFR was measured according to method in the literature.45.After
urine collection, rats were anesthetized with an intraperitoneal
injection of pentobarbital sodium (30 mg/kg) and were placed on a
heated table to maintain core temperature between 37 1C and 38 1C.
Trachea, both jugular veins, and right carotid artery were
catheterized with polyethylene tubing PE-240 and PE-50. Then the
rats were treated with an infusion of 4% inulin (Farco Chemical
a b
c
Figure 8 | Triptolide reversed podocyte synaptopodin distribution in PAN-induced injury. Untreated podocytes (a). Podocytes were
treated with PAN (100 mg/ml, 24 h) followed by culture medium for further 72 h (b). Podocytes were treated with PAN (100 mg/ml, 24 h)
followed by triptolide medium for further 72 h (c). Green fluorochrome corresponds to synaptopodin and red to the nucleus.
Original magnification  400.
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Supplies, Hong Kong, China) diluted in 0.9% saline solution at
2.0 ml/h by left jugular vein. Urine was drained from the bladder
with a PE-50 tube. After surgery, rats were maintained under
euvolemic conditions by infusing 10 ml/kg of body weight of
isotonic rat plasma by left jugular vein. After an equilibrium period
of 120 min, urine was collected for 60 min and blood samples were
taken by right carotid artery at the beginning and end of the urine
collection period. Mean inulin concentrations in urine and plasma
were determined with anthrone reagent. Appropriate plasma and
urine blanks, collected before inulin infusion, were run for each
a b c
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Control PAN Triptolide pretreatment +PAN
Figure 9 | Triptolide protected podocytes against PAN-induced nephrin and podocin alteration. (a–c) Green fluorochrome corresponds
to nephrin and red to the nucleus. (d–f) Green fluorochrome corresponds to podocin and red to the nucleus. Untreated podocytes (a, d).
PAN (100mg/ml) treated podocytes (b, e). Podocytes were preincubated for 30 min with triptolide before PAN exposure (c, f). Original
magnification  400.
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determination. Inulin was calculated by the standard formula GFR
(ml/min*100 g body weight)¼U*V/P, where U is the concentration
of inulin in urine, V is urine flow rate, and P is the concentration of
inulin in plasma.
Foot processes width measure
Each photograph was analyzed with SimplePCI software (Compix
Co., Irvine, CA, USA). The curved length of the peripheral capillary
basement membrane was measured, the number of slit diaphragms
a b c
d e f
Control PAN PAN + triptolide treatment
Figure 11 | Triptolide restored the expression of podocytes nephrin and podocin in PAN-induced injury. Green fluorochrome
corresponds to nephrin and red to the nucleus (a–c). Green fluorochrome corresponds to podocin and red to the nucleus (d–f). Untreated
podocytes (a, d). Podocytes were treated with PAN (100mg/ml, 24 h) followed by culture medium for further 72 h (b, e). Podocytes
were treated with PAN (100 mg/ml, 24 h) followed by culture medium with triptolide for further 72 h (c, f). Original magnification  400.
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Figure 12 | Triptolide restored podocytes nephrin and podocin expression analyzed by flow cytometry. MFI of nephrin (a). MFI of
podocin (b). Panels on the left represent untreated podocytes. Middle panels represent podocytes were treated with PAN (100 mg/ml, 24 h)
followed by culture medium without triptolide for further 72 h. Panels on the right represent podocytes were treated with PAN
(100mg/ml, 24 h) followed by culture medium with triptolide for further 72 h.
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overlying the capillary basement membrane was counted, and the
average foot process width (Wp, nm) was calculated using the
formula in the literature.46
Immunofluorescence staining
Cryosections measuring 4 mm were stained with mouse anti-rat
nephrin antibody, monoclonal antibody 5-1-6 (1:400; a gift from
professor Hiroshi Kawachi in Niigata University, Japan), and rabbit
anti-rat podocin antibody (1:200; Sigma), followed by treatment
with fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG
(1:50; Dako, Carpinteria, CA, USA) and swine anti-rabbit IgG (1:50;
Dako). Sections were examined by immunofluorescence microscopy
(Nikon Eclipse E800, Tokyo, Japan). All exposure parameters were
kept constant for each section.
Immunohistochemistry
After de-waxing, 2 mm sections were stained with mouse anti-rat
desmin antibody (1:200; Dako), followed by incubation with the
Dako Envision system (ready to use; Dako). Sections were then
visualized with 3-amino-9-ethyl-carbazole and counterstained with
hematoxylin.
TUNEL staining
Apoptosis cells were detected with the In Situ Cell Death Detection
kit, Fluorescein (Roche Applied Science, Indianapolis, IN, USA)
according to the manufacturer’s protocol. Briefly, 4 mm cryostat
kidney sections were fixed with 4% paraformaldehyde and incubated
with permeabilization solution for 2 min on ice. The negative
control sections were incubated only in label solution and the
positive control sections were treated with 50 U/ml DNaseI (Sigma)
prior to labeling procedures. Then sections were incubated with
enzyme solution. Finally, sections were observed by immuno-
fluorescence microscopy.
Mouse podocyte culture
Conditionally immortalized mouse podocytes were a kind gift from
Professor Stuart J Shankland (University of Washington, Seattle,
WA, USA). Podocytes were cultured in RPMI-1640 medium
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Figure 13 | Roles of the ROS- and p38 MAPK-signaling pathways in the protective effect of triptolide. Time course of PAN-induced
cellular ROS generation (a). Triptolide inhibited ROS generation in PAN-treated podocytes (b). Time course of PAN on p38 MAPK activation
(c). Triptolide diminished p38 MAPK activation in PAN-treated podocytes (d). (e–h) Cellular ROS and p38 MAPK activation are required
for PAN-induced actin reorganization in podocytes. Untreated podocytes (e); PAN (100 mg/ml, 24 h) treated podocytes (f); podocytes
were preincubated for 30 min with NAC before PAN exposure (g); podocytes were preincubated for 30 min with SB-203580 before
PAN exposure (h). All above results presented are representative of three independent experiments. Values are expressed as
mean±s.d.; *Po0.01 versus time point 0.
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containing 10% fetal bovine serum, 100 U/ml penicillin, and
100mg/ml streptomycin (Gibco-BRL, Gaithersburg, MD, USA).
Podocytes were expanded by culture in medium containing 10 U/ml
mouse interferon-g (R&D Systems, Minneapolis, MN, USA) at
33 1C. Removal of interferon-g and switching growth temperature to
37 1C for 10B14 days caused podocytes to stop proliferating and
undertake a differentiated phenotype.14
Reagents treatments
Podocyte injury was induced by treatment with 25B100mg/ml
PAN for 24 h. The protective and recovering effects of triptolide
were observed. For the protective effect experiments, podocytes
were preincubated for 30 min with triptolide (0.5B3 ng/ml)
before PAN exposure. There were three groups, including
normal control, PAN injury, and triptolide pretreatment groups.
While for recovering effect experiments, the culture medium
was changed to medium with or without triptolide (3 ng/ml)
after 24 h of PAN treatment, antioxidant (NAC, 10 mmol/l),
inhibitor of p38 MAPK, SB-203580(25 mmol/l), and RhoA inhi-
bitor, and C3 exoenzyme (1mg/ml), were administered 30 min
before PAN.
Apoptosis detection by Hoechst 33342
Differentiated podocytes were grown on chamber slides. After
treatment, cells were fixed in 4% paraformaldehyde and mounted in
10 mmol/l Hoechst 33342. Apoptosis was defined as the presence of
nuclear condensation on Hoechst staining, and the percentage of the
cells with nuclear condensation was calculated on at least 300
consecutive cells. All experiments were performed a minimum of
three times.
Immunofluorescence staining of podocytes
Cells were fixed in 4% paraformaldehyde and then permeablized
with 0.5% Triton X-100. For cytoskeletal staining, cells were
incubated with 0.5 ng/ml rhodamine–phalloidin (Cytoskeleton
Company, Denver, CO, USA) for 40 min. As for synaptopodin and
slit diaphragm proteins staining, cells were stained with rabbit anti-
mouse synatopodin antibody (ready to use; Fitzgerald, Concord,
CA, USA), rabbit anti-mouse nephrin antibody (1:50, a gift from
professor David J Salant in Boston University, Boston, MA, USA),
and rabbit anti-mouse podocin antibody (1:50; Sigma), followed by
treatment with fluorescein isothiocyanate-conjugated swine anti-
rabbit IgG (1:50; Dako). Cells were then counterstained with
100 nmol/l propidium iodide. Cells were observed and imaged by
confocal microscopy (LSM 510; Carl Zeiss, Jena, Germany).
Flow cytometry analysis of nephrin and podocin expression
Nephrin and podocin expression were quantified by flow cytometry
(FACS Aria; Becton Dickinson, San Jose, CA, USA). Cells were
harvested and fixed in 4% paraformaldehyde and permeated with
0.1% saponin. Aliquots of 1 106 cells/ml were incubated for 30 min
with antibodies of nephrin (1:50) and podocin (1:50), and then
incubated with fluorescein isothiocyanate-conjugated swine anti-
rabbit IgG (1:50, Dako) for 30 min. Quantitative changes in
antigenic expression were assessed using mean fluorescence intensity
(MFI).
ROS assay
The intracellular production of ROS was assayed using the
fluoroprobe CM-H2DCFDA (chloromethyl-2, 7-dichlorodihydro-
fluorescein diacetate; Molecular Probes, Eugene, OR, USA). To
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Figure 14 | Role of the RhoA-signaling pathway in the protective effect of triptolide. Time course of RhoA activity inhibited by PAN in
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examine the effect of PAN on ROS generation by podocytes,
podocytes were stimulated with 100 mg/ml PAN for 0.5, 1, 3, 6, 12,
and 24 h. To determine the effect of triptolide on PAN-stimulated
ROS generation, podocytes were preincubated for 30 min with
triptolide (3 ng/ml) before PAN exposure. After treatment, cells were
loaded with 10mmol/l CM-H2DCFDA. Cells were immediately
analyzed by flow cytometry. For each sample, 10,000 events were
collected and the content of ROS was assessed by MFI.
Western blot analysis of total and phospho-p38 MAPK
Cells were lysed in cold cell lysis buffer (50 mM Tris, 150 mM NaCl,
10 mM ethylenediaminetetraacetic acid, 1% Triton X-100) contain-
ing protease and phosphatase inhibitors. The cell lysates (50 mg)
were heated for 5 min at 95 1C in sample buffer, separated on 10%
SDS–polyacrylamide gel, and transferred onto nitrocellulose mem-
brane. Membranes were probed with rabbit polyclonal antibody to
p38 MAPK, phosphospecific p38 MAPK, and glyceraldehyde-
3-phosphate dehydrogenase (1:1000; Santa Cruz Biotechnology,
Waltham, MA, USA) and then were reprobed with horseradish
peroxidase-conjugated anti-rabbit antibody (1:1000; Santa Cruz
Biotechnology) and visualized by enhanced chemiluninecence
detection.
RhoA activation assay by pull-down experiment
RhoA activation was studied using the RhoA activation kit
(Cytoskeleton Inc., Denver, CO, USA) according to the manufac-
turer’s recommendations. After cell lysis, about 300mg of protein
was incubated with 50 mg of Rhotekin-RBD protein beads (GST
fusion protein containing the RhoA-binding domain of Rhotekin).
The bound proteins were fractionated on 12% SDS-polyacrylamide-
gel electrophoresis and immunoblotted with anti-RhoA monoclonal
antibody. The level of active RhoA was determined after normal-
ization with the total RhoA presented in the cell lysates.
Statistical analysis
Statistical analyses were performed with SPSS software (version
11.5). Results were expressed as mean±s.d. Student’s t-test was used
to compare difference between groups. Po0.05 was considered
statistically significant and Po0.01 was considered of high statistical
significance.
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